- Trial phase
- Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
- Time to market
- Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
- Why 4/10
- Tenapanor is already approved and commercialized in two indications with no pending regulatory decision. The next hard catalyst is the Phase 3 ACCEL CIC topline readout, expected in H2 2027 (more than 12 months away). Since there is no dated binary catalyst within ~12 months, the impact score is capped at 5. The drug is the sole revenue driver for Ardelyx, but the defining binary events (initial approvals) have already passed, and commercial execution is a gradual, non-binary driver.
Tenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.
Price Chart
Executive Summary
Tenapanor is Ardelyx's only commercial product, sold under two brands: IBSRELA for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for hyperphosphatemia in dialysis patients. It is a first-in-class NHE3 inhibitor that works locally in the gut. In Q3 2026, the two brands generated $125.5M in combined product revenue (+19% YoY), with IBSRELA contributing $96.3M (+23%) and XPHOZAH $29.2M (+7%). The company is nearing profitability (net loss narrowed to $0.7M) and has $285M cash. The next major catalyst is the Phase 3 ACCEL trial readout for chronic idiopathic constipation, expected in H2 2027, which is more than 12 months away. Analyst consensus is strongly bullish (16 of 17 analysts rate Buy/Strong Buy) with a mean price target of $12.80, implying 289% upside from the current $3.29 price.
How It Works
Tenapanor is a pill that blocks a protein called NHE3 in the gut. By blocking this sodium 'pump,' it keeps more water in the intestines, which softens stool and makes bowel movements easier (used for IBS-C). It also reduces how much phosphate the body absorbs from food, which helps dialysis patients with high phosphate levels (hyperphosphatemia).
Trial Status
Tenapanor is already FDA-approved in two indications: IBSRELA for IBS-C (approved September 2019) and XPHOZAH for hyperphosphatemia in dialysis patients (approved October 2023). Ardelyx completed enrollment ahead of schedule in the Phase 3 ACCEL trial evaluating tenapanor for chronic idiopathic constipation (CIC), with topline data expected in the second half of 2027. Pediatric trials in IBS-C have completed: a Phase 3 in adolescents 12-18 years and a Phase 2 in children 6-12 years.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ACCEL CIC topline data (H2 2027)
- Pediatric IBS-C trial data readouts
- RDX10531 next-generation NHE3 inhibitor preclinical/early clinical updates
- Quarterly earnings reports tracking revenue growth trajectory
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ardelyx, Inc. PRESS-RELEASE ARDX ·Originating report